{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T17:56:52Z","timestamp":1771610212860,"version":"3.50.1"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,3,25]],"date-time":"2019-03-25T00:00:00Z","timestamp":1553472000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hered Cancer Clin Pract"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s13053-019-0111-y","type":"journal-article","created":{"date-parts":[[2019,3,25]],"date-time":"2019-03-25T13:02:41Z","timestamp":1553518961000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":53,"title":["The effect of neoadjuvant platinum-based chemotherapy in BRCA mutated triple negative breast cancers -systematic review and meta-analysis"],"prefix":"10.1186","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0825-6732","authenticated-orcid":false,"given":"Olga","family":"Caramelo","sequence":"first","affiliation":[]},{"given":"Cristina","family":"Silva","sequence":"additional","affiliation":[]},{"given":"Francisco","family":"Caramelo","sequence":"additional","affiliation":[]},{"given":"Cristina","family":"Frutuoso","sequence":"additional","affiliation":[]},{"given":"Teresa","family":"Almeida-Santos","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2019,3,25]]},"reference":[{"issue":"8","key":"111_CR1","doi-asserted-by":"publisher","first-page":"2329","DOI":"10.1158\/1078-0432.CCR-06-1109","volume":"13","author":"LA Carey","year":"2007","unstructured":"Carey LA, Dees EC, Sawyer L, Gatti L, Moore DT, Collichio F, Ollila DW, Sartor CI, Graham ML, Perou CM. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res. 2007;13(8):2329\u201334.","journal-title":"Clin Cancer Res"},{"issue":"15 Pt 1","key":"111_CR2","doi-asserted-by":"publisher","first-page":"4429","DOI":"10.1158\/1078-0432.CCR-06-3045","volume":"13","author":"R Dent","year":"2007","unstructured":"Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, Lickley LA, Rawlinson E, Sun P, Narod SA. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res. 2007;13(15 Pt 1):4429\u201334.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"111_CR3","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1007\/s10549-008-0086-2","volume":"115","author":"R Dent","year":"2009","unstructured":"Dent R, Hanna WM, Trudeau M, Rawlinson E, Sun P, Narod SA. Pattern of metastatic spread in triple-negative breast cancer. Breast Cancer Res Treat. 2009;115(2):423\u20138.","journal-title":"Breast Cancer Res Treat"},{"issue":"Suppl 6","key":"111_CR4","doi-asserted-by":"publisher","first-page":"vi7","DOI":"10.1093\/annonc\/mds187","volume":"23","author":"P Boyle","year":"2012","unstructured":"Boyle P. Triple-negative breast cancer: epidemiological considerations and recommendations. Ann Oncol. 2012;23(Suppl 6):vi7\u201312.","journal-title":"Ann Oncol"},{"issue":"4","key":"111_CR5","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1158\/1055-9965.EPI-08-1005","volume":"18","author":"JM Dolle","year":"2009","unstructured":"Dolle JM, Daling JR, White E, Brinton LA, Doody DR, Porter PL, Malone KE. Risk factors for triple-negative breast cancer in women under the age of 45 years. Cancer Epidemiol Biomark Prev. 2009;18(4):1157\u201366.","journal-title":"Cancer Epidemiol Biomark Prev"},{"issue":"1","key":"111_CR6","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1111\/j.1365-2559.2007.02889.x","volume":"52","author":"JS Reis-Filho","year":"2008","unstructured":"Reis-Filho JS, Tutt AN. Triple negative tumours: a critical review. Histopathology. 2008;52(1):108\u201318.","journal-title":"Histopathology"},{"issue":"18","key":"111_CR7","doi-asserted-by":"publisher","first-page":"2966","DOI":"10.1200\/JCO.2009.25.9549","volume":"28","author":"M Colleoni","year":"2010","unstructured":"Colleoni M, Cole BF, Viale G, Regan MM, Price KN, Maiorano E, Mastropasqua MG, Crivellari D, Gelber RD, Goldhirsch A, et al. Classical cyclophosphamide, methotrexate, and fluorouracil chemotherapy is more effective in triple-negative, node-negative breast cancer: results from two randomized trials of adjuvant chemoendocrine therapy for node-negative breast cancer. J Clin Oncol. 2010;28(18):2966\u201373.","journal-title":"J Clin Oncol"},{"issue":"9938","key":"111_CR8","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/S0140-6736(13)62422-8","volume":"384","author":"P Cortazar","year":"2014","unstructured":"Cortazar P, Zhang L, Untch M, Mehta K, Costantino JP, Wolmark N, Bonnefoi H, Cameron D, Gianni L, Valagussa P, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet. 2014;384(9938):164\u201372.","journal-title":"Lancet"},{"issue":"8","key":"111_CR9","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1200\/JCO.2007.14.4147","volume":"26","author":"C Liedtke","year":"2008","unstructured":"Liedtke C, Mazouni C, Hess KR, Andre F, Tordai A, Mejia JA, Symmans WF, Gonzalez-Angulo AM, Hennessy B, Green M, et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol. 2008;26(8):1275\u201381.","journal-title":"J Clin Oncol"},{"issue":"7","key":"111_CR10","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/S1470-2045(14)70160-3","volume":"15","author":"G Minckwitz von","year":"2014","unstructured":"von Minckwitz G, Schneeweiss A, Loibl S, Salat C, Denkert C, Rezai M, Blohmer JU, Jackisch C, Paepke S, Gerber B, et al. Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial. Lancet Oncol. 2014;15(7):747\u201356.","journal-title":"Lancet Oncol"},{"issue":"1","key":"111_CR11","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1200\/JCO.2014.57.0572","volume":"33","author":"WM Sikov","year":"2015","unstructured":"Sikov WM, Berry DA, Perou CM, Singh B, Cirrincione CT, Tolaney SM, Kuzma CS, Pluard TJ, Somlo G, Port ER, et al. Impact of the addition of carboplatin and\/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance). J Clin Oncol. 2015;33(1):13\u201321.","journal-title":"J Clin Oncol"},{"issue":"2","key":"111_CR12","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1002\/path.4280","volume":"232","author":"BD Lehmann","year":"2014","unstructured":"Lehmann BD, Pietenpol JA. Identification and use of biomarkers in treatment strategies for triple-negative breast cancer subtypes. J Pathol. 2014;232(2):142\u201350.","journal-title":"J Pathol"},{"key":"111_CR13","first-page":"93","volume":"8","author":"J Collignon","year":"2016","unstructured":"Collignon J, Lousberg L, Schroeder H, Jerusalem G. Triple-negative breast cancer: treatment challenges and solutions. Breast Cancer (Dove Med Press). 2016;8:93\u2013107.","journal-title":"Breast Cancer (Dove Med Press)"},{"issue":"7418","key":"111_CR14","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/nature11412","volume":"490","author":"Cancer Genome Atlas N","year":"2012","unstructured":"Cancer Genome Atlas N. Comprehensive molecular portraits of human breast tumours. Nature. 2012;490(7418):61\u201370.","journal-title":"Nature"},{"issue":"26","key":"111_CR15","doi-asserted-by":"publisher","first-page":"4282","DOI":"10.1200\/JCO.2008.16.6231","volume":"26","author":"DP Atchley","year":"2008","unstructured":"Atchley DP, Albarracin CT, Lopez A, Valero V, Amos CI, Gonzalez-Angulo AM, Hortobagyi GN, Arun BK. Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer. J Clin Oncol. 2008;26(26):4282\u20138.","journal-title":"J Clin Oncol"},{"issue":"1","key":"111_CR16","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1158\/1055-9965.EPI-11-0775","volume":"21","author":"N Mavaddat","year":"2012","unstructured":"Mavaddat N, Barrowdale D, Andrulis IL, Domchek SM, Eccles D, Nevanlinna H, Ramus SJ, Spurdle A, Robson M, Sherman M, et al. Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1\/2 (CIMBA). Cancer Epidemiol Biomark Prev. 2012;21(1):134\u201347.","journal-title":"Cancer Epidemiol Biomark Prev"},{"issue":"11","key":"111_CR17","doi-asserted-by":"publisher","first-page":"2787","DOI":"10.1002\/cncr.26576","volume":"118","author":"AR Hartman","year":"2012","unstructured":"Hartman AR, Kaldate RR, Sailer LM, Painter L, Grier CE, Endsley RR, Griffin M, Hamilton SA, Frye CA, Silberman MA, et al. Prevalence of BRCA mutations in an unselected population of triple-negative breast cancer. Cancer. 2012;118(11):2787\u201395.","journal-title":"Cancer"},{"issue":"3","key":"111_CR18","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1007\/s10549-014-2980-0","volume":"145","author":"P Sharma","year":"2014","unstructured":"Sharma P, Klemp JR, Kimler BF, Mahnken JD, Geier LJ, Khan QJ, Elia M, Connor CS, McGinness MK, Mammen JM, et al. Germline BRCA mutation evaluation in a prospective triple-negative breast cancer registry: implications for hereditary breast and\/or ovarian cancer syndrome testing. Breast Cancer Res Treat. 2014;145(3):707\u201314.","journal-title":"Breast Cancer Res Treat"},{"issue":"10","key":"111_CR19","doi-asserted-by":"publisher","first-page":"3254","DOI":"10.1245\/s10434-013-3205-1","volume":"20","author":"R Greenup","year":"2013","unstructured":"Greenup R, Buchanan A, Lorizio W, Rhoads K, Chan S, Leedom T, King R, McLennan J, Crawford B, Kelly Marcom P, et al. Prevalence of BRCA mutations among women with triple-negative breast cancer (TNBC) in a genetic counseling cohort. Ann Surg Oncol. 2013;20(10):3254\u20138.","journal-title":"Ann Surg Oncol"},{"issue":"Suppl 1","key":"111_CR20","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1038\/ejhg.2016.93","volume":"24","author":"D Stoppa-Lyonnet","year":"2016","unstructured":"Stoppa-Lyonnet D. The biological effects and clinical implications of BRCA mutations: where do we go from here? Eur J Hum Genet. 2016;24(Suppl 1):S3\u20139.","journal-title":"Eur J Hum Genet"},{"issue":"10","key":"111_CR21","doi-asserted-by":"publisher","first-page":"1378","DOI":"10.1001\/jamaoncol.2017.1007","volume":"3","author":"E Hahnen","year":"2017","unstructured":"Hahnen E, Lederer B, Hauke J, Loibl S, Krober S, Schneeweiss A, Denkert C, Fasching PA, Blohmer JU, Jackisch C, et al. Germline mutation status, pathological complete response, and disease-free survival in triple-negative breast cancer: secondary analysis of the GeparSixto randomized clinical trial. JAMA Oncol. 2017;3(10):1378\u201385.","journal-title":"JAMA Oncol"},{"issue":"4","key":"111_CR22","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1007\/s12254-017-0368-7","volume":"10","author":"R Bartsch","year":"2017","unstructured":"Bartsch R, Bergen E. ASCO 2017: highlights in breast cancer. Memo. 2017;10(4):228\u201332.","journal-title":"Memo"},{"issue":"Suppl 5","key":"111_CR23","doi-asserted-by":"publisher","first-page":"v8","DOI":"10.1093\/annonc\/mdv298","volume":"26","author":"E Senkus","year":"2015","unstructured":"Senkus E, Kyriakides S, Ohno S, Penault-Llorca F, Poortmans P, Rutgers E, Zackrisson S, Cardoso F, Committee EG. Primary breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26(Suppl 5):v8\u201330.","journal-title":"Ann Oncol"},{"key":"111_CR24","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.breast.2017.07.017","volume":"35","author":"S Paluch-Shimon","year":"2017","unstructured":"Paluch-Shimon S, Pagani O, Partridge AH, Abulkhair O, Cardoso MJ, Dent RA, Gelmon K, Gentilini O, Harbeck N, Margulies A, et al. ESO-ESMO 3rd international consensus guidelines for breast cancer in young women (BCY3). Breast. 2017;35:203\u201317.","journal-title":"Breast"},{"issue":"8","key":"111_CR25","doi-asserted-by":"publisher","first-page":"1700","DOI":"10.1093\/annonc\/mdx308","volume":"28","author":"G Curigliano","year":"2017","unstructured":"Curigliano G, Burstein HJ, Winer EP, Gnant M, Dubsky P, Loibl S, Colleoni M, Regan MM, Piccart-Gebhart M, Senn HJ, et al. De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen international expert consensus conference on the primary therapy of early breast cancer 2017. Ann Oncol. 2017;28(8):1700\u201312.","journal-title":"Ann Oncol"},{"key":"111_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/2046-4053-4-1","volume":"4","author":"D Moher","year":"2015","unstructured":"Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, Shekelle P, Stewart LA, Group P-P. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev. 2015;4:1.","journal-title":"Syst Rev"},{"issue":"2","key":"111_CR27","doi-asserted-by":"publisher","first-page":"310","DOI":"10.5114\/aoms.2012.28559","volume":"8","author":"A Kolacinska","year":"2012","unstructured":"Kolacinska A, Chalubinska J, Blasinska-Morawiec M, Dowgier-Witczak I, Fendler W, Kordek R, Morawiec Z. Pathological complete response in younger and older breast cancer patients. Arch Med Sci. 2012;8(2):310\u20135.","journal-title":"Arch Med Sci"},{"issue":"4","key":"111_CR28","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/S1470-2045(18)30111-6","volume":"19","author":"S Loibl","year":"2018","unstructured":"Loibl S, O'Shaughnessy J, Untch M, Sikov WM, Rugo HS, McKee MD, Huober J, Golshan M, von Minckwitz G, Maag D, et al. Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial. Lancet Oncol. 2018;19(4):497\u2013509.","journal-title":"Lancet Oncol"},{"key":"111_CR29","doi-asserted-by":"publisher","first-page":"d4002","DOI":"10.1136\/bmj.d4002","volume":"343","author":"JA Sterne","year":"2011","unstructured":"Sterne JA, Sutton AJ, Ioannidis JP, Terrin N, Jones DR, Lau J, Carpenter J, Rucker G, Harbord RM, Schmid CH, et al. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. BMJ. 2011;343:d4002.","journal-title":"BMJ"},{"issue":"2","key":"111_CR30","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1007\/s10549-014-3100-x","volume":"147","author":"T Byrski","year":"2014","unstructured":"Byrski T, Huzarski T, Dent R, Marczyk E, Jasiowka M, Gronwald J, Jakubowicz J, Cybulski C, Wisniowski R, Godlewski D, et al. Pathologic complete response to neoadjuvant cisplatin in BRCA1-positive breast cancer patients. Breast Cancer Res Treat. 2014;147(2):401\u20135.","journal-title":"Breast Cancer Res Treat"},{"key":"111_CR31","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1007\/s10549-018-4727-9","volume":"170","author":"K Clifton","year":"2018","unstructured":"Clifton K, Gutierrez-Barrera A, Ma J, Bassett R Jr, Litton J, Kuerer H, Moulder S, Albarracin C, Hortobagyi G, Arun B. Adjuvant versus neoadjuvant chemotherapy in triple-negative breast cancer patients with BRCA mutations. Breast Cancer Res Treat. 2018;170:101.","journal-title":"Breast Cancer Res Treat"},{"issue":"8","key":"111_CR32","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1097\/CAD.0000000000000260","volume":"26","author":"X Guan","year":"2015","unstructured":"Guan X, Ma F, Fan Y, Zhu W, Hong R, Xu B. Platinum-based chemotherapy in triple-negative breast cancer: a systematic review and meta-analysis of randomized-controlled trials. Anti-Cancer Drugs. 2015;26(8):894\u2013901.","journal-title":"Anti-Cancer Drugs"},{"issue":"2","key":"111_CR33","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1007\/s10549-014-2876-z","volume":"144","author":"F Petrelli","year":"2014","unstructured":"Petrelli F, Coinu A, Borgonovo K, Cabiddu M, Ghilardi M, Lonati V, Barni S. The value of platinum agents as neoadjuvant chemotherapy in triple-negative breast cancers: a systematic review and meta-analysis. Breast Cancer Res Treat. 2014;144(2):223\u201332.","journal-title":"Breast Cancer Res Treat"},{"key":"111_CR34","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1093\/jnci\/djx258","volume":"110","author":"O Gluz","year":"2017","unstructured":"Gluz O, Nitz U, Liedtke C, Christgen M, Grischke EM, Forstbauer H, Braun M, Warm M, Hackmann J, Uleer C, et al. Comparison of neoadjuvant nab-paclitaxel+carboplatin vs nab-paclitaxel+gemcitabine in triple-negative breast cancer: randomized WSG-ADAPT-TN trial results. J Natl Cancer Inst. 2017;110:628.","journal-title":"J Natl Cancer Inst"},{"key":"111_CR35","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1093\/annonc\/mdy127","volume":"29","author":"F Poggio","year":"2018","unstructured":"Poggio F, Bruzzone M, Ceppi M, Ponde NF, La Valle G, Del Mastro L, de Azambuja E, Lambertini M. Platinum-based neoadjuvant chemotherapy in triple-negative breast cancer: a systematic review and meta-analysis. Ann Oncol. 2018;29:1497.","journal-title":"Ann Oncol"},{"issue":"suppl_5","key":"111_CR36","doi-asserted-by":"publisher","first-page":"168P","DOI":"10.1093\/annonc\/mdx362.018","volume":"28","author":"C Fontaine","year":"2017","unstructured":"Fontaine C, Cappoen N, Renard V, Van Den Bulk H, Vuylsteke P, Glorieux P, De Gr\u00e8ve J, Decoster L, Vanhoeij M, Awada A, et al. Updated results of the breast cancer task force phase II study of neoadjuvant weekly carboplatin (Cp) added to paclitaxel (P) followed by epirubicin (E) and cyclophosphamide (C) in triple negative breast cancer (TNBC) patients (pts). Ann Oncol. 2017;28(suppl_5):168P.","journal-title":"Ann Oncol"},{"issue":"15_suppl","key":"111_CR37","doi-asserted-by":"publisher","first-page":"TPS587","DOI":"10.1200\/JCO.2017.35.15_suppl.TPS587","volume":"35","author":"GM Kim","year":"2017","unstructured":"Kim GM, Jeung H-C, Jung KH, Kim SH, Kim HJ, Lee KH, Park KH, Lee JE, Ahn MS, Kohn S, et al. PEARLY: A randomized, multicenter, open-label, phase III trial comparing anthracyclines followed by taxane versus anthracyclines followed by taxane plus carboplatin as (neo)adjuvant therapy in patients with early triple-negative breast cancer. J Clin Oncol. 2017;35(15_suppl):TPS587.","journal-title":"J Clin Oncol"},{"issue":"suppl_8","key":"111_CR38","doi-asserted-by":"publisher","first-page":"243P","DOI":"10.1093\/annonc\/mdy270.238","volume":"29","author":"E Pohl","year":"2018","unstructured":"Pohl E, Schneeweiss A, Hauke J, Rhiem K, Weber-Lassalle N, Schmutzler RK, Untch M, Luebbe K, Jackisch C, Moebus V, et al. Germline mutation status and therapy response in patients with triple-negative breast cancer (TNBC): Results of the GeparOcto study. Ann Oncol. 2018;29(suppl_8):243P.","journal-title":"Ann Oncol"},{"issue":"15_suppl","key":"111_CR39","doi-asserted-by":"publisher","first-page":"TPS591","DOI":"10.1200\/JCO.2017.35.15_suppl.TPS591","volume":"35","author":"HM Earl","year":"2017","unstructured":"Earl HM, Vallier A-L, Qian W, Grybowicz L, Thomas S, Mahmud S, Harvey C, McAdam K, Hughes-Davies L, Roylance R, et al. PARTNER: Randomised, phase II\/III trial to evaluate the safety and efficacy of the addition of olaparib to platinum-based neoadjuvant chemotherapy in triple negative and\/or germline BRCA mutated breast cancer patients. J Clin Oncol. 2017;35(15_suppl):TPS591.","journal-title":"J Clin Oncol"},{"issue":"15_suppl","key":"111_CR40","doi-asserted-by":"publisher","first-page":"e13008","DOI":"10.1200\/JCO.2016.34.15_suppl.e13008","volume":"34","author":"M Frolova","year":"2016","unstructured":"Frolova M, Ignatova E, Stenina MB, Petrovsky A, Tjulandin S. Role of different germline BRCA mutations in response to platinum-based chemotherapy in patients (pts) with triple-negative breast cancer (TNBC). J Clin Oncol. 2016;34(15_suppl):e13008.","journal-title":"J Clin Oncol"},{"issue":"3","key":"111_CR41","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1007\/s10549-015-3435-y","volume":"151","author":"VG Kaklamani","year":"2015","unstructured":"Kaklamani VG, Jeruss JS, Hughes E, Siziopikou K, Timms KM, Gutin A, Abkevich V, Sangale Z, Solimeno C, Brown KL, et al. Phase II neoadjuvant clinical trial of carboplatin and eribulin in women with triple negative early-stage breast cancer (NCT01372579). Breast Cancer Res Treat. 2015;151(3):629\u201338.","journal-title":"Breast Cancer Res Treat"},{"issue":"17","key":"111_CR42","doi-asserted-by":"publisher","first-page":"1895","DOI":"10.1200\/JCO.2014.57.0085","volume":"33","author":"ML Telli","year":"2015","unstructured":"Telli ML, Jensen KC, Vinayak S, Kurian AW, Lipson JA, Flaherty PJ, Timms K, Abkevich V, Schackmann EA, Wapnir IL, et al. Phase II study of gemcitabine, carboplatin, and iniparib as neoadjuvant therapy for triple-negative and BRCA1\/2 mutation-associated breast cancer with assessment of a tumor-based measure of genomic instability: PrECOG 0105. J Clin Oncol. 2015;33(17):1895\u2013901.","journal-title":"J Clin Oncol"},{"issue":"5","key":"111_CR43","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1038\/s41591-018-0009-7","volume":"24","author":"A Tutt","year":"2018","unstructured":"Tutt A, Tovey H, Cheang MCU, Kernaghan S, Kilburn L, Gazinska P, Owen J, Abraham J, Barrett S, Barrett-Lee P, et al. Carboplatin in BRCA1\/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT trial. Nat Med. 2018;24(5):628\u201337.","journal-title":"Nat Med"},{"key":"111_CR44","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1200\/JCO.2009.22.4725","volume":"28","author":"DP Silver","year":"2010","unstructured":"Silver DP, Richardson AL, Eklund AC, Wang ZC, Szallasi Z, Li Q, Juul N, Leong CO, Calogrias D, Buraimoh A, Fatima A, Gelman RS, Ryan PD, Tung NM, De Nicolo A, Ganesan S, Miron A, Colin C, Sgroi DC, Ellisen LW, Winer EP, Garber JE (2010) Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer. J Clin Oncol 28:1145-1153. doi: 10.1200\/JCO.2009.22.4725.","journal-title":"J Clin Oncol"},{"key":"111_CR45","doi-asserted-by":"publisher","unstructured":"Sharma P, Lopez-Tarruella S, Garcia-Saenz JA, Ward C, Connor CS, Gomez HL, Prat A, Moreno F, Jerez-. Gilarranz Y, Barnadas A, Picornell AC, Del Monte-Millan M, Gonzalez-Rivera M, Massarrah T. Pelaez.Lorenzo B, Palomero MI, Gonzalez Del Val R, Cortes J, Fuentes Rivera H, Bretel Morales D. Marquez-Rodas I, Perou CM, Wagner JL, Mammen JM, McGuiness MK, Klemp JR, Amin AL, Fabian CJ. Heldstab J, Godwin AK, Jensen RA, Kimler BF, Jhan QJ, Martin M (2017) Efficacy of Neoadjuvant. Carboplatin plus Docetaxel in Triple-Negative Breast Cancer: Combined Analysis of Two Cohort. Clin. Cancer Res 23:649\u2013657. \n                    https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-0162\n                    \n                  .","DOI":"10.1158\/1078-0432.CCR-16-0162"},{"key":"111_CR46","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.breast.2018.05.007","volume":"40","author":"T Sella","year":"2018","unstructured":"Sella T, Gal Yam EN, Levanon K, Rotenberg TS, Gadot M, Kuchuk I, Molho RB, Itai A, Modiano TM, Gold R, Kaufman B, Shimon SP (2018) Evaluation of tolerability and efficacy of incorporating carboplatin in neoadjuvant anthracycline and taxane based therapy in a BRCA1 enriched triple-negative breast cancer cohort. Breast 40:141-146. \n                    https:\/\/doi.org\/10.1016\/j.breast.2018.05.007\n                    \n                  .","journal-title":"Breast"}],"container-title":["Hereditary Cancer in Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13053-019-0111-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s13053-019-0111-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13053-019-0111-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,3,24]],"date-time":"2020-03-24T00:21:13Z","timestamp":1585009273000},"score":1,"resource":{"primary":{"URL":"https:\/\/hccpjournal.biomedcentral.com\/articles\/10.1186\/s13053-019-0111-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,25]]},"references-count":46,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["111"],"URL":"https:\/\/doi.org\/10.1186\/s13053-019-0111-y","relation":{},"ISSN":["1897-4287"],"issn-type":[{"value":"1897-4287","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,25]]},"assertion":[{"value":"10 January 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 March 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"11"}}